MPN Clinical Trials

Clinical trials are an important step in the process of discovering new treatments for MPNs. The decision to participate in a clinical trial is one you should carefully consider. It is important to discuss clinical trial participation with your family and your physician. We've compiled a FAQ to assist patients who are considering participating in a clinical trial.

The MPN Research Foundation has complied a list of trials, some of which are currently recruiting patients:

If you are a company or investigator who is running a trial and you need to make a change to the listing for your trial contact our office at 312-683-7243 or by sending an email.

Find a Clinical Trial

Click the boxes below to filter clinical trials by disease type.

All
Myelofibrosis (MF)
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)
MF

PAC203 | Pacritinib | Posted 6/26/17

CTI Biopharma is recruiting patients for the PAC203 study, a randomized phase 2 trial evaluating different doses of pacritinb in myelofibrosis patients with platelets less than 100,000/microliter and who have previously received ruxolitinib (Jakafi/Jakavi). Please see the link below for more information.

CTIBiopharma www.CTIBiopharma.com
Click here for more information about PAC203

MF

Luspatercept | Posted 7/13/2017

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence.


For more information, please refer to NCT03194542 on ClinicalTrials.gov

Or Click here for more information.

 

ETMF

RESET-272 | Posted 6/15/2017

A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

https://clinicaltrials.gov/ct2/results?term=NCT03123588&Search=Search

MF

Ruxolitinib + Thalidomide

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis https://clinicaltrials.gov/ct2/show/NCT03069326?term=thalidomide+AND+ruxolitinib&rank=1

MF

INCB050465 | Posted 6/15/2017

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis.Click here for trial information. 

 

ETPV

Ruxolitinib - Ruxo-BEAT trial

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT) Click here for trail information.

MFPV

TGR-1202 + Ruxolitinib

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea. Click here for more information. 

MF

Ruxolitinib - Early Myelofibrosis

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. Click here for trial information. 

ET

Ruxolitinib vs BAT in High Risk ET

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line.  Click here for trial information. 

MF

PIM447 + Ruxolitinib

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis.  Click here for trial information. 

MF

Eltrombopag

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis.  Click here for trial information. 

 

MF

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC)

MF

Nivolumab

Phase 2 study of Nivolumab in myelofibrosis. This drug uses a person's immune system to fight disease. Find out more: https://clinicaltrials.gov/ct2/show/NCT02421354?term=nivolumab+myelofibrosis&rank=1

 

ETMFPV

PU-H71

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies. For more information contact: John Gerecitano, MD, PhD 212-639-3748 OR Shanu Modi, MD 646-888-5243
ETMFPV

CPI-0610

A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/ Myeloproliferative Neoplasms, and Myelofibrosis. For more information contact Debbie Johnson at

debbie.johnson@constellationpharma.com

 

MF

Durvalumab

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis For more information contact the  Study Coordinator at 312-695-1301 or cancertrials@northwestern.edu

 

MF

Phase 2 LCL-161

For Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Sponsor: MD Anderson in collaboration with Novartis

Contact: Serge Verstovsek, MD at 713-792-7305 or sverstov@mdanderson.org

ETPV

Open Label Study of Single Agent Oral RG7388

Sponsor: John Mascerenhas

Contact: John Mascarenhas, MD at (212) 241-3417 or john.mascarenhas@mssm.edu

Jill Kleczko at (212)241-0573 or jill.kleczko@mssm.edu

ETPV

Pegasys

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Contact: Dr. Ronald Hoffman at ronald.hoffman@mssm.edu or 212-241-2296

ETMFPV

* Familial Study of MPDs

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Contact: Dr. Josef Prchal at 801-581-4220 or Kim Hickman at 801-581-3707

PV

* AOP2014 and Hydroxyurea

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

Contact: Michael Zoerer at 43+1+5037244-46 , OR michael.zoerer@aoporphan.com

PV

Pegylated Interferon

AOP2014 in patients with Polycythemia Vera who previously participated in the PROUD-PV study

Contact: Michael Zoerer at michael.zoerer@aoporphan.com / 43+1+5037244-46 OR check clinicaltrials.gov

ETMFPV

Mirabegron

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Contact: Andrea Fuhrer, PhD at +41 31 389 92 63 OR andrea.fuhrer@sakk.ch

MF

SL-401

Phase I/II trial of SL-401 in patients with advanced, high risk MPNs, including MF, CMML, advanced systemic mastocytosis and HES/CEL

Contact: Srdan Verstovsek, MD, PhD at 713-745-3429

MF

Research Tissue Bank

Study allows for the preservation and storage of a small portion of tissues to be used for the study of MPDs.

Contact: Rona S. Weinberg, PhD at 212-570-3412 OR rweinberg@nybloodcenter.org

MF

Correlative Bio-Marker Study

Correlative Biomarker Study in Patients with Myeloproliferative Disorders

Contact: Rona S. Weinberg, PhD at 212-570-3412 OR rweinberg@nybloodcenter.org

Ronald Hoffman, MD at 212-241-2297 OR ronald.hoffman@mssm.edu

MF

Sotatercept (ACE-011)

Phase II, open-label study of sotatercept (ACE-011) in subjects with MF & significant anemia

Contact: Srdan Verstovsek, MD, PhD, at 713-745-3429

MF

TAK-901

A Phase 1 Dose Escalation Study of TAK-901 in Subjects with Advanced Hematological Malignancies

Contact: Millennium Medical or Drug Info Center at 877-674-3784 OR medical@mlnm.com

MF

Pegasys

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Contact: Thomas S. Larsen at thomas.stauffer.larsen@ouh.regionsyddanmark.dk or

Sally Grant at sally.grant@ouh.regionsyddanmark.dk

MF

Ruxolitinib & Pracinostat

Evaluation of Ruxolitinib & Pracinostat Combination as a therapy for Patients with Myelofibrosis

Contact: Srdan Verstovsek, MD, PhD at 713-745-3429

MF

INC424

INC424 for Patients with Myelofibrosis (JUMP)

Contact: Novartis Pharmaceuticals at +1-862-778-8300

MF

* NS-018

Safety and Tolerability Study of Oral NS-018 in Patients with Myelofibrosis (MF) previously treated with a Janus Kinase Inhibitor,

(https://clinicaltrials.gov/ct2/show/NCT01423851For more information, contact Tomonori Uno of NS Pharma at: uno@nspharma.com

MF

Oral Arsenic

Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults with Myelofibrosis

Contact: Roswell Park Cancer Center Institute at 877-275-7724 or askrpci@rosewellpark.org

MF

* LCL-161

Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Contact: Naveen Pemmaraju, MD at 713-792-4956

MF

Pomalidomide

Study of Pomalidomide in Persons with Myelofibrosis (RESUME)

Contact: Mary Bartlett at 913-266-0513 or mbartlett@celgene.com

Alyce Kay at 913-266-0369 or akay@celgene.com

MF

Ruxolitinib & Panobinostst

Panobinostat and Ruxolitinib in myelofibrosis (Prime Study) - Phase I/II study of combination oral JAK2 tyrosine kinase inhibotor (JAK2-TKI) and histone deacetylase inhibitor (HDACI) therapy in patients with myelofibrosis

Contact: Jill Kleczko at jill.kleczko@mssm.edu or

John Mascarenhas at john.mascarenhas@mssm.edu

MF

Ruxolitinib & LDE225

A Phase1b/11 Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Contact: Novartis at 41-61-3241111

MF

Ruxolitinib & SCT

Exploring the potential of dual kinase JAK1/2 inhibitor Ruxolitinib (INC424) with reduced intensity allogenic hematopoeitic stem cell transplantation in patients with myelofibrosis (MPD-RC #114)

Contact: Jill Kleczko at jill.kleczko@mssm.edu,

Vikas Gupta at 416-946-4521,

Adam Mead at adam.mead@imm.ox.ac.uk OR 44-0-1865-222325, or

John Mascarenhas at john.mascarenhas@mssm.edu

MF

PRM-151

A Phase 2, Prospective Study of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)

More information is available at http://www.promoteclinicaltrials.com/ or please contact: promote@promedior.com.

MF

P1101 Ropeginterferon Alpha-2b | Updated 6/26/2017

This pilot phase II trial studies P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with early myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of early myelofibrosis. More information available here: http://www.mpnresearchfoundation.org/PharmaEssentia-Corp.

Contact: Allison Rosenthal at Rosenthal.Allison@mayo.edu

MF

Ruxolitinib with Allogeneic Hematopoeitic Cell Transplantation

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis.

Contact: Sara Duffey, Clinical Research and Education Specialist , Robert H. Lurie Comprehensive Cancer Center at 312.695.1102 or cancertrials@northwestern.edu

MF

Alisertib (MLN8237)

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinases, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)

For more information about this study please contact us at: 312.472.123 or at nmdti@northwestern.edu

MF

PF-04449913

PF-04449913 Single-Agent In Patients With Myelofibrosis Previously Treated With a Janus Kinase Inhibitor

Pfizer Clinical Trial Call Center: 1-800-718-1021 or contact us here

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe